Vanguard Fiduciary Trust
HOWL icon

Vanguard Fiduciary Trust’s Werewolf Therapeutics HOWL Stock Holding History

Vanguard Fiduciary Trust’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.8K Hold
157,726
– – ﹤0.01% 3844
2026
Q1 		$131K Buy
+157,726
New +$108K ﹤0.01% 3650

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Fiduciary Trust's HOWL Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Werewolf Therapeutics (HOWL) position steady in Q2 2026 at 157,726 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3844.

Vanguard Fiduciary Trust first reported a position in HOWL in Q1 2026 and has held it in 2 quarters since. The position peaked at $131K in Q1 2026. 42 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Vanguard Fiduciary Trust held 157,726 shares of Werewolf Therapeutics worth $56.8K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Werewolf Therapeutics share count unchanged in Q2 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3844 holding.
  • Vanguard Fiduciary Trust first reported a position in Werewolf Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Werewolf Therapeutics position peaked at $131K in Q1 2026.
  • 42 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.